Zephex® – Channelling over 30 years of experience into the future of medical propellants in MDIs

The Zephex® brand stands for quality, reliability, and leadership in medical propellants for pressurized metered-dose inhalers (pMDIs).

Zephex® medical propellants are trusted by leading pharmaceutical companies worldwide to ensure delivery of life-saving respiratory medicines, safely and effectively for patients with asthma, COPD and other respiratory diseases.

Launched over 30 years ago, the Zephex® brand is the most established and widely used medical propellant brand in the world.

Orbia Fluor & Energy Materials is helping lead the low-global warming potential (low-GWP) transition via its Zephex® brand; having introduced Zephex® 152a to the market.

This low-GWP propellant is helping drive the industry towards the low-GWP transition, while maintaining the high performance, safety, and reliability expected from the Zephex® name.

The Zephex® brand continues to support 100 million patients in accessing life-saving medication every year.

Zephex® – Channelling over 30 years of experience into the future of medical propellants in MDIs

The Zephex® brand stands for quality, reliability, and leadership in medical propellants for pressurized metered-dose inhalers (pMDIs).

Zephex® medical propellants are trusted by leading pharmaceutical companies worldwide to ensure delivery of life-saving respiratory medicines, safely and effectively for patients with asthma, COPD and other respiratory diseases.

Launched over 30 years ago, the Zephex® brand is the most established and widely used medical propellant brand in the world.

Orbia Fluor & Energy Materials is helping lead the low-global warming potential (low-GWP) transition via its Zephex® brand; having introduced Zephex® 152a to the market.

This low-GWP propellant is helping drive the industry towards the low-GWP transition, while maintaining the high performance, safety, and reliability expected from the Zephex® name.

The Zephex® brand continues to support 100 million patients in accessing life-saving medication every year.